Transaction successfully completes Nordion’s strategic review, subject to closing, delivering value to shareholders Shareholders to receive an aggregate cash consideration of US $11.75 per share Nordion to hold conference call and webcast at 8:00 am ET on Monday, March 31, 2014 to discuss the announcement…
OTTAWA, Ontario–(BUSINESS WIRE)–Mar. 4, 2014— Nordion Inc. (TSX:NDN) (NYSE:NDZ) announced today that it has entered into a two-year contract with Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a global leading company in the diagnostic imaging business, to supply strontium-82, a cyclotron based…
Industry leaders hear about the latest irradiation developments at IMRP 2013
OTTAWA, Ontario–(BUSINESS WIRE)–Nov. 4, 2013 — Nordion, a leading supplier of Cobalt-60 and a global leader in the design and construction of commercial gamma irradiation systems, today joins the International Irradiation Association (iiA) and other industry leaders at the 2013 International Meeting on Radiation Processing (IMRP) in Shanghai, China…
Capability Opens New Market Opportunities to Ultra-Low Power Memory Products
OTTAWA, Canada–(BUSINESS WIRE)–Oct. 16, 2013 — Adesto Technologies, a memory solutions provider delivering innovative products for code and data storage applications, and Nordion, with global expertise in the design and construction of commercial gamma irradiation systems, today announced the successful completion of gamma irradiation testing of Adesto’s CBRAM non-volatile memory products…
OTTAWA, Ontario–(BUSINESS WIRE)–Jul. 15, 2013 — Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services to the global health science market, today announced that it has completed the divestiture of its Targeted Therapies business to BTG plc (LSE: BTG), an international specialist healthcare company based in London, United Kingdom for a cash purchase price of US$200 million…
OTTAWA, Ontario–(BUSINESS WIRE)–May. 23, 2013 — Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services for the prevention, diagnosis and treatment of disease, announced that it has entered into an agreement to divest its Targeted Therapies business to BTG…
Interventional Oncology Team at Northwestern Memorial Hospital to perform hepatocellular carcinoma liver-directed treatment with live narration
OTTAWA, Ontario–(BUSINESS WIRE)–May. 16, 2013 — Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services for the prevention, diagnosis and treatment of disease, today announced that for the second consecutive year, organizers of the World Congress on Interventional Oncology (WCIO) 2013 will host a live administration of TheraSphere®, Nordion’s Yttrium-90 (Y-90) glass microspheres for the treatment of hepatocellular carcinoma (HCC)…
OTTAWA, Ontario–(BUSINESS WIRE)–May. 15, 2013 — Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services to the global health science market, today announced it has signed a contract manufacturing agreement with Navidea Biopharmaceuticals, a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals…
Session to complement Nordion’s educational portfolio for physicians
OTTAWA, Ontario–(BUSINESS WIRE)–Apr. 10, 2013 — Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services for the prevention, diagnosis and treatment of disease, will host an educational session called “TheraSphere® Test Flight Interactive: How to Treat or Should I Treat?” at the Society for Interventional Radiologists (SIR) Annual Scientific Meeting, taking place April 13-18 in New Orleans, Louisiana…
Meetings designed to support TheraSphere® treatment growth and expansion in Europe
OTTAWA, Ontario–(BUSINESS WIRE)–Apr. 9, 2013 — Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services for the prevention, diagnosis and treatment of disease, will host two upcoming educational and scientific meetings to support the growth and expansion of TheraSphere® treatment in Europe…
